Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Pepparedsleden 1, Mölndal, 431 83, Sweden.
AstraZeneca MPI Satellite Unit, Abteilung Chemische Biologie, Max Planck Institut für Molekulare Physiologie, Dortmund, Germany.
Angew Chem Int Ed Engl. 2017 Aug 21;56(35):10294-10323. doi: 10.1002/anie.201611914. Epub 2017 Jul 24.
Our ever-increasing understanding of biological systems is providing a range of exciting novel biological targets, whose modulation may enable novel therapeutic options for many diseases. These targets include protein-protein and protein-nucleic acid interactions, which are, however, often refractory to classical small-molecule approaches. Other types of molecules, or modalities, are therefore required to address these targets, which has led several academic research groups and pharmaceutical companies to increasingly use the concept of so-called "new modalities". This Review defines for the first time the scope of this term, which includes novel peptidic scaffolds, oligonucleotides, hybrids, molecular conjugates, as well as new uses of classical small molecules. We provide the most representative examples of these modalities to target large binding surface areas such as those found in protein-protein interactions and for biological processes at the center of cell regulation.
我们对生物系统的认识不断加深,为许多疾病提供了一系列令人兴奋的新型生物靶点,这些靶点的调节可能为许多疾病提供新的治疗选择。这些靶点包括蛋白质-蛋白质和蛋白质-核酸相互作用,但这些靶点通常对经典的小分子方法有抗性。因此,需要其他类型的分子或方式来解决这些靶点,这导致了几个学术研究小组和制药公司越来越多地使用所谓的“新方式”的概念。本综述首次定义了这一术语的范围,包括新型肽支架、寡核苷酸、杂交物、分子缀合物,以及对经典小分子的新用途。我们提供了这些方式的最具代表性的例子,这些方式针对的是蛋白质-蛋白质相互作用等大结合表面区域,以及细胞调节中心的生物过程。